Syncona Limited Autolus announces confidential filing for potential IPO

 
TIDMSYNC 
 
Syncona Limited 
 
          Autolus announces confidential submission for potential IPO 
 
6 March 2018 
 
Syncona Ltd, a leading healthcare company focused on investing in and building 
global leaders in life science, today notes the announcement from its portfolio 
company, Autolus, that it has made a confidential submission of a draft 
registration statement on Form F-1 to the U.S. Securities and Exchange 
Commission relating to a potential initial public offering of ordinary shares 
in the United States. 
 
The process is at a preliminary stage and an initial public offering may or may 
not be pursued by Autolus. Syncona is the largest shareholder in Autolus and is 
highly supportive of the company over the long term in line with Syncona's 
strategy to build global leaders in life science and deliver transformational 
treatments to patients. 
 
This announcement is being made pursuant to and in accordance with Rule 135 
under the U.S. Securities Act of 1933, as amended, and does not constitute an 
offer to sell or the solicitation of an offer to buy securities, and shall not 
constitute an offer, solicitation or sale in any jurisdiction in which such 
offer, solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of that jurisdiction. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Siobhan Weaver 
Tel: [phone] 
[phone] 
 
Tulchan Communications 
Martin Robinson 
Lisa Jarrett-Kerr 
Tel: [phone] 
 
Copies of this press release and other corporate information can be found on 
the company website at: www.synconaltd.com 
 
Forward-looking statements - this announcement contains certain forward-looking 
statements with respect to the portfolio of investments of Syncona Ltd. These 
statements and forecasts involve risk and uncertainty because they relate to 
events and depend upon circumstances that may or may not occur in the future. 
There are a number of factors that could cause actual results or developments 
to differ materially from those expressed or implied by these forward-looking 
statements and forecasts. Nothing in this announcement should be construed as a 
profit forecast. 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

March 06, 2018 02:00 ET (07:00 GMT)